-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense Therapeutics Granted Parent From U.S. Patent And Trademark Office For Use Of PrimeC Combination In Alzheimer' Disease

Benzinga·01/21/2026 13:45:18
Listen to the news

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,527,768, entitled "Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases."

The granted patent provides protection for the use of PrimeC combination in Alzheimer's disease, strengthening NeuroSense's intellectual property estate and supporting the program's long-term development and potential commercialization, with protection extending through 2043.